Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia | Zendy

Luzelena Caro | Zendy; David P. Nicolau | Zendy; Jan J. De Waele | Zendy; Joseph L. Kuti | Zendy; Kajal Larson | Zendy; Elaine Gadzicki | Zendy; Brian Yu | Zendy; Zhen Zeng | Zendy; Adedayo Adedoyin | Zendy; Elizabeth G. Rhee | Zendy

Open Access

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia

Author(s) -

Luzelena Caro,

David P. Nicolau,

Jan J. De Waele,

Joseph L. Kuti,

Kajal Larson,

Elaine Gadzicki,

Brian Yu,

Zhen Zeng,

Adedayo Adedoyin,

Elizabeth G. Rhee

Publication year - 2020

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkaa049

Subject(s) - medicine , pharmacokinetics , pharmacodynamics , pneumonia , dosing , tazobactam , adverse effect , bacterial pneumonia , pharmacology , anesthesia , antibiotics , antibiotic resistance , imipenem , microbiology and biotechnology , biology

Ceftolozane/tazobactam is approved for hospital-acquired/ventilator-associated bacterial pneumonia at double the dose (i.e. 2 g/1 g) recommended for other indications. We evaluated the bronchopulmonary pharmacokinetic/pharmacodynamic profile of this 3 g ceftolozane/tazobactam regimen in ventilated pneumonia patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research